https://www.jnj.com/rss-feed/all.rss RSS feed all en-US Thu, 11 Jun 2026 12:22:39 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-expands-u-s-availability-of-tecnis-puresee-iol-an-advanced-lens-option-for-cataract-surgeons-and-patients • Expanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery. • Cataracts are one of the leading causes of vision impairment.1 Nearly 20% of Americans aged 40+ live with cataracts that make everyday tasks more challenging, yet only 5% have had cataract surgery.2 • Over half a million eyes worldwide have already experienced clearer, extended range of vision with TECNIS PureSee IOL after cataract surgery.3,4 • 97% of patients would recommend TECNIS PureSee IOL to friends or family.5 Thu, 11 Jun 2026 12:22:39 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-expands-u-s-availability-of-tecnis-puresee-iol-an-advanced-lens-option-for-cataract-surgeons-and-patients https://www.jnj.com/media-center/press-releases/imaavy-nipocalimab-aahu-demonstrates-durable-hemoglobin-response-and-rapid-onset-of-effect-in-pivotal-phase-2-3-study-in-warm-autoimmune-hemolytic-anemia-waiha-an-autoantibody-driven-disease-with-no-fda-approved-therapies · Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as early as Week 1c · More patients treated with IMAAVY experienced improvement in fatigued and corticosteroid dose reductionse · IMAAVY is designed to target pathogenic immunoglobulin G (IgG) autoantibodies in warm autoimmune hemolytic anemia while preserving immune function · Pivotal results will be presented at EHA 2026 Thu, 11 Jun 2026 11:36:49 GMT https://www.jnj.com/media-center/press-releases/imaavy-nipocalimab-aahu-demonstrates-durable-hemoglobin-response-and-rapid-onset-of-effect-in-pivotal-phase-2-3-study-in-warm-autoimmune-hemolytic-anemia-waiha-an-autoantibody-driven-disease-with-no-fda-approved-therapies https://www.jnj.com/media-center/press-releases/depuy-synthes-launches-velys-hip-navigation-with-ai-to-support-intraoperative-consistency-and-efficiency-in-total-hip-arthroplasty Use of VELYS™ Hip Navigation with AI Assistance demonstrated reproducible landmark identification and reduced workflow time by 57% compared to manual workflows (5.33 vs. 2.27 minutes) 1 Tue, 09 Jun 2026 12:02:14 GMT https://www.jnj.com/media-center/press-releases/depuy-synthes-launches-velys-hip-navigation-with-ai-to-support-intraoperative-consistency-and-efficiency-in-total-hip-arthroplasty https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-firefly-bio-inc-to-expand-oncology-pipeline-with-novel-degrader-antibody-conjugate-platform • Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation Mon, 08 Jun 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-firefly-bio-inc-to-expand-oncology-pipeline-with-novel-degrader-antibody-conjugate-platform https://www.jnj.com/media-center/press-releases/johnson-johnson-late-breaking-results-show-nipocalimab-significantly-reduced-systemic-lupus-erythematosus-sle-disease-activity-in-a-phase-2-study · Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with this disease while preserving immune function · Results demonstrated significant reduction of systemic lupus erythematosus disease activity which continued beyond the 24-week primary endpoint, and were sustained through Week 52 in the nipocalimab 15 mg/kg groupa · The ongoing Phase 3 study of nipocalimab is currently recruiting people living with systemic lupus erythematosus – a debilitating autoantibody-driven disease which can lead to systemic organ damage Wed, 03 Jun 2026 12:00:18 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-late-breaking-results-show-nipocalimab-significantly-reduced-systemic-lupus-erythematosus-sle-disease-activity-in-a-phase-2-study https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-data-further-reinforcing-the-role-of-nipocalimab-in-lowering-the-autoantibodies-driving-sjogrens-disease · Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren’s disease while preserving immune function · New exploratory analysis of Phase 2 study data shows a strong correlation between autoantibody levels and even greater clinical response rates of participants in the nipocalimab treatment group · Previously reported data from the Phase 2 study showed nipocalimab reduced Sjögren’s disease activity and severity, with potential to address systemic manifestations and the most burdensome patient-reported symptoms including dryness, fatigue and pain · Nipocalimab is the only FcRn blocker granted both Breakthrough Therapy Designation and Fast Track Designation by the U.S. FDA for the treatment of adults with moderate-to-severe Sjögren’s disease. Wed, 03 Jun 2026 11:46:36 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-data-further-reinforcing-the-role-of-nipocalimab-in-lowering-the-autoantibodies-driving-sjogrens-disease https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-pivotal-data-show-strong-and-durable-responses-in-advanced-head-and-neck-cancer-where-options-remain-limited • More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publication • RYBREVANT FASPRO™, an EGFR- and MET-targeting dual inhibitor, is the first and only subcutaneous therapy being evaluated in this setting • Johnson & Johnson submitted a supplemental Biologics License Application to U.S. FDA seeking approval for this indication Sun, 31 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-pivotal-data-show-strong-and-durable-responses-in-advanced-head-and-neck-cancer-where-options-remain-limited https://www.jnj.com/media-center/press-releases/johnson-johnson-phase-3-prostate-cancer-study-shows-erleada-apalutamide-before-and-after-surgery-significantly-reduces-risk-of-metastasis-or-death-breaking-a-decades-long-treatment-paradigm • Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death • Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of Medicine Sun, 31 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-phase-3-prostate-cancer-study-shows-erleada-apalutamide-before-and-after-surgery-significantly-reduces-risk-of-metastasis-or-death-breaking-a-decades-long-treatment-paradigm https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-demonstrates-prolonged-clinical-benefit-as-a-first-line-treatment-for-atypical-egfr-mutated-non-small-cell-lung-cancer • Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease • Consistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomes • ASCO 2026 results reinforce the significance of RYBREVANT®-based regimens for patients across EGFR mutations Fri, 29 May 2026 18:00:00 GMT https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-demonstrates-prolonged-clinical-benefit-as-a-first-line-treatment-for-atypical-egfr-mutated-non-small-cell-lung-cancer https://www.jnj.com/media-center/press-releases/new-tecvayli-data-demonstrates-superior-progression-free-and-overall-survival-as-early-as-first-relapse-in-multiple-myeloma • Building on the recent approval of TECVAYLI® plus DARZALEX FASPRO®, MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI® as early as second line • TECVAYLI®delivered deep and durable responses, with nearly two-thirds of patients achieving a complete response or better Fri, 29 May 2026 12:33:37 GMT https://www.jnj.com/media-center/press-releases/new-tecvayli-data-demonstrates-superior-progression-free-and-overall-survival-as-early-as-first-relapse-in-multiple-myeloma https://www.jnj.com/media-center/press-releases/fda-approves-label-expansion-cementing-tremfya-as-the-only-il-23-inhibitor-proven-to-help-stop-further-joint-damage TREMFYA® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis Thu, 28 May 2026 23:40:38 GMT https://www.jnj.com/media-center/press-releases/fda-approves-label-expansion-cementing-tremfya-as-the-only-il-23-inhibitor-proven-to-help-stop-further-joint-damage https://www.jnj.com/media-center/press-releases/johnson-johnson-to-host-investor-conference-call-on-second-quarter-results-2026 Wed, 27 May 2026 20:22:40 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-host-investor-conference-call-on-second-quarter-results-2026 https://www.jnj.com/media-center/press-releases/depuy-synthes-announces-agreement-to-acquire-miniature-radiofrequency-tracking-technology-across-its-joint-reconstruction-portfolio Agreement will bring first-to-market capabilities to eliminate line-of-sight dependency designed to improve simplicity and surgical flow Tue, 26 May 2026 12:01:00 GMT https://www.jnj.com/media-center/press-releases/depuy-synthes-announces-agreement-to-acquire-miniature-radiofrequency-tracking-technology-across-its-joint-reconstruction-portfolio https://www.jnj.com/media-center/press-releases/depuy-synthes-enters-exclusive-u-s-canada-and-australia-distribution-agreement-for-cgbios-novosis Partnership strengthens DePuy Synthes’ portfolio with a differentiated bone graft substitute containing growth factors to address unmet need across orthopaedic specialties Tue, 26 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/depuy-synthes-enters-exclusive-u-s-canada-and-australia-distribution-agreement-for-cgbios-novosis https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-creation-of-global-intelligent-or-network-in-collaboration-with-department-of-health-abu-dhabi Department of Health – Abu Dhabi standardizes operating rooms on Polyphonic™ to empower clinicians and advance global AI Building on collaboration with AWS and NVIDIA, the effort expands the ecosystem of healthcare and technology leaders scaling surgical innovation Thu, 21 May 2026 11:00:06 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-creation-of-global-intelligent-or-network-in-collaboration-with-department-of-health-abu-dhabi https://www.jnj.com/media-center/press-releases/groundbreaking-global-survey-captures-the-significant-patient-burden-experienced-with-current-standard-of-care-bladder-cancer-treatments-underscoring-urgency-for-continued-innovation • More than 90% of patients surveyed who underwent bladder removal or received BCG report negative impact on most aspects of their lives • Among patients treated with BCG, three-quarters describe managing the treatment-related physical symptoms as humiliating • Patients and urologists point to the importance of advancing treatments that may better reflect patient preferences and quality‑of‑life considerations Thu, 14 May 2026 20:06:43 GMT https://www.jnj.com/media-center/press-releases/groundbreaking-global-survey-captures-the-significant-patient-burden-experienced-with-current-standard-of-care-bladder-cancer-treatments-underscoring-urgency-for-continued-innovation https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-hematology-leadership-with-30-presentations-at-the-2026-european-hematology-association-eha-congress · Johnson & Johnson will present 30+ abstracts at European Hematology Association 2026, highlighting leadership in hematology with data across multiple myeloma and leukemia, and first pivotal data in warm autoimmune hemolytic anemia · Phase 3 results evaluate the potentially transformative investigational combination of TALVEY®, the first GPRC5D‑targeted bispecific antibody, in combination with DARZALEX FASPRO® with or without pomalidomide for patients with relapsed or refractory multiple myeloma in earlier lines of therapy · Pivotal Phase 2/3 results potentially position IMAAVY® as the first FDA-approved treatment for warm autoimmune hemolytic anemiaa designed to target the IgG autoantibodies responsible for red blood cell destruction Tue, 12 May 2026 20:54:53 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-hematology-leadership-with-30-presentations-at-the-2026-european-hematology-association-eha-congress https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-the-standard-of-calcium-modification-with-global-launch-of-shockwave-c2-aero-coronary-ivl-catheter • Next-generation intravascular lithotripsy (IVL) catheter resets physicians’ expectations by addressing unmet needs in deliverability, lesion crossing and balloon repositioning • Shockwave C2 Aero enables clinicians to extend Shockwave IVL’s clinically-validated mechanism of action to a broader spectrum of calcified coronary lesions Tue, 12 May 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-the-standard-of-calcium-modification-with-global-launch-of-shockwave-c2-aero-coronary-ivl-catheter https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference Mon, 11 May 2026 20:37:14 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference https://www.jnj.com/media-center/press-releases/johnson-johnson-reinforces-its-leadership-in-advancing-neuropsychiatry-with-new-portfolio-and-pipeline-data-at-apa-and-ascp Oral presentations feature CAPLYTA® long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms 18 abstracts highlight J&J’s leadership and deep portfolio in neuropsychiatry at the American Psychiatric Association (APA) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings Mon, 11 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-reinforces-its-leadership-in-advancing-neuropsychiatry-with-new-portfolio-and-pipeline-data-at-apa-and-ascp https://www.jnj.com/media-center/press-releases/johnson-johnson-launches-generation-fine-a-new-movement-encouraging-patients-to-expect-more-from-depression-treatment-and-aim-for-remission Generation Fine launches after global survey finds nearly 4 in 5 patients living with major depressive disorder don’t believe antidepressants will help them reach remission Campaign draws on expertise of Mental Health America and elevates the voices of leading mental health advocates, including Kyle Long, television studio analyst, retired National Football League (NFL) player Thu, 07 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-launches-generation-fine-a-new-movement-encouraging-patients-to-expect-more-from-depression-treatment-and-aim-for-remission https://www.jnj.com/media-center/press-releases/johnson-johnson-investigational-co-antibody-therapy-jnj-4804-shows-potential-to-raise-the-bar-for-clinical-efficacy-in-treating-refractory-inflammatory-bowel-disease JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn’s disease who have had inadequate response to two or more systemic therapy classes JNJ-4804 is the first and only fixed dose co-antibody designed to deliver molecular synergy in IBD by blocking the complementary IL-23 and TNF pathways Data from Phase 2b DUET studies show potential to address a critical unmet need and support advancement to Phase 3 trials Tue, 05 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-investigational-co-antibody-therapy-jnj-4804-shows-potential-to-raise-the-bar-for-clinical-efficacy-in-treating-refractory-inflammatory-bowel-disease https://www.jnj.com/media-center/press-releases/johnson-johnson-study-shows-tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-demonstrate-efficacy-in-perianal-fistulizing-crohns-disease TREMFYA® demonstrated significantly higher rates of combined fistula remission – complete external closure of draining fistulas and absence of fluid collection on MRI – compared to placebo at Week 24 First study of its kind in 20 years for this debilitating manifestation of Crohn’s disease presented as late-breaking data at Digestive Disease Week (DDW) 2026 Tue, 05 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-study-shows-tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-demonstrate-efficacy-in-perianal-fistulizing-crohns-disease https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-pivotal-clinical-study-results-for-a-new-soft-tissue-surgical-robotic-system Study results represent a critical milestone for the investigational OTTAVA™ Robotic Surgical System Data demonstrates feasibility of novel system architecture with table‑integrated robotic arms in space‑constrained ORs Abstract presented at the 2026 American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting Presidential Grand Round Sessions in San Antonio, Texas Tue, 05 May 2026 11:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-pivotal-clinical-study-results-for-a-new-soft-tissue-surgical-robotic-system https://www.jnj.com/media-center/press-releases/promising-data-from-us-pilot-study-shows-planned-impella-5-5-use-is-safe-and-feasible-in-non-shock-high-risk-cardiac-surgery-patients Mon, 04 May 2026 20:30:00 GMT https://www.jnj.com/media-center/press-releases/promising-data-from-us-pilot-study-shows-planned-impella-5-5-use-is-safe-and-feasible-in-non-shock-high-risk-cardiac-surgery-patients